Chemours Shares Slide After Q2 Results and Weakened Guidance
Chemours shares plunged 15.6% in morning trading to $15.13 after the company reported second-quarter 2026 results that missed analyst expectations on both adjusted earnings and revenue. Management issued cautious near-term guidance - including a narrowed, lower full-year EBITDA range - and said the core TSS segment is facing mix-driven margin press…